Leucettamol A
Leucettamol A is an inhibitor of Ubc13 (ubiquitin E2 enzyme) -Uev1A interaction, with an IC50 of 50 μg/mL. Leucettamol A can potentially activate the expression of cancer suppressor p53 and is a precursor of anticancer agents. Leucettamol A can be isolated from a marine sponge, Leucetta aff. Microrhaphis[1][2].
Product Specifications
CAS Number
151124-32-2
UNSPSC
12352211
Target
E1/E2/E3 Enzyme; MDM-2/p53
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/leucettamol-a.html
Smiles
C[C@@H](N)[C@@H](O)C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC[C@H](O)[C@H](N)C
Molecular Formula
C30H52N2O2
Molecular Weight
472.75
References & Citations
[1]Sachiko Tsukamoto, et al. Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. Microrhaphis. Bioorg Med Chem Lett. 2008 Dec 15;18 (24) :6319-20.|[2]Kimberli M Helms, et al. Vitexin inhibits polyubiquitin synthesis by the ubiquitin-conjugating enzyme E2-25K. Nat Prod Commun. 2011 Oct;6 (10) :1411-6.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
